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Abstract
Certain laminins of vascular basement membranes have been
identified in human breast tumors and brain gliomas that share the
same  β1 chain. These laminins are new carcinoma angiogenic
markers and might represent potential targets for antiangiogenic
therapy.
Breast cancer is the leading cause of death from malignant
tumors in women. In recent years, various biomarkers
associated with breast cancer growth and angiogenesis have
been described. The process of angiogenesis has attracted
considerable interest as a target for cancer therapy, and
inhibitors of the process may be less toxic than conventional
chemotherapy as well as being associated with a lower risk of
drug resistance. On the basis of these discoveries, several
clinical trials are using angiogenesis inhibitors: type I
inhibitors block a single angiogenic protein (such as vascular
endothelial growth factor (VEGF)), type II inhibitors block two
or three proteins (VEGF, basic fibroblast growth factor (FGF-2),
and transforming growth factor-α (TGF-α)), and type III
inhibitors have a broad spectrum of antiangiogenic targets.
Angiogenesis might also be blocked by inhibiting the HER-2
proto-oncogene, epidermal growth factor receptor (EGFR),
extracellular matrix (ECM) components and matrix
metalloproteinases (MMPs) [1,2]. However, only Avastin, an
anti-VEGF antibody, has been so far approved by the US
Food and Drug Administration for the treatment of metastatic
colon cancer, and is the first angiogenesis inhibitor
demonstrated to prolong survival in a large multicenter
randomized, placebo-controlled, clinical trial [2]. Treatment
based on small daily dosages of chemotherapy, metronomic
therapy, is also considered effective as an antiangiogenic
therapy with few side effects [3]. For breast cancer, there is a
need to develop the best combination of antiangiogenic
drugs based on new biomarkers of tumor progression and
angiogenesis that could be used alone or with conventional
chemotherapy.
Experimental evidence described in this issue of Breast
Cancer Research by Julia Ljubimova and colleagues in Los
Angeles [4] implicates several laminin isoforms that are major
basement membrane (BM) components in the progression of
human breast tumors.
BMs represent specialized ECM laid down around
parenchymal and vascular endothelial cells. BMs consist of
many components, some of which are found in all these
structures and some of which are only included in few
specialized BMs. Type IV collagens, laminins, nidogens, and
perlecan are generally regarded as ubiquitous BM
components. Matrilins, dystroglycans, fibronectin, bamacan,
β-netrin, and other collagen types are found in only some
BMs and often in pathological conditions. Both type IV
collagens and laminins have multiple isoforms, which creates
an even greater diversity of BM composition in various
organs. Our present state of knowledge requires the
identification of specific isoforms of these proteins in a
specific BM [5-8].
BMs are important in tumor progression as barriers for
invasion, as migration substrata for tumor cells, and as
components of newly formed tumor blood vessels [9-11]. In
many solid tumors, BMs are discontinuous or absent [11].
This seems to result both from the inability of tumor cells to
secrete and assemble BM components and degrade BM
properly. It is generally recognized that the proteolytic
degradation of ECM and BM mediated by the plasminogen
activator (PA) system and various MMPs may facilitate tumor
cell migration and invasion [12].
The laminin family of glycoproteins is a major constituent of
both epithelial and vascular BMs. All laminins consist of three
covalently linked chains, namely α,  β, and γ. So far, 15
members of this family have been identified [5,6,8], although
the first 12 are the better studied. Laminins interact with cells
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through various receptors that mostly belong to the family of
integrin heterodimers. In different cell types, integrins α1β1,
α2β1, α3β1, α6β1, α6β4, and α7β1 have been reported to
bind to laminins. Specific laminin isoforms bind some but not
all of these different integrins, and each integrin can bind
more than one laminin isoform [13,14]. Of particular
importance for vascular BMs is laminin-8 (α4β1γ1). It
supports cell migration [15] and may be associated with
tumor invasion [16]. Knockout of laminin-8 α4 chain is
characterized by abnormal blood vessel maturation [17].
Another laminin isoform that is abundant in vascular BMs is
laminin-10 (α5β1γ1).
Fujita and colleagues [4] have identified three BM laminins that
share the same β1 chain, namely laminin-2 (α2β1γ1), laminin-8,
and laminin-10, as new breast carcinoma angiogenic markers.
Their expression, determined by the detection of β1 and other
chains, was increased in the walls of ductal breast carcinoma
blood vessels. A switch of laminin isoforms from laminin-9 and
laminin-11 to laminin-8 and laminin-10 – that is, from β2-
containing to β1-containing laminins – was detected during
breast cancer progression for the first time. Laminin-8 was
shown to be present in 20% of ductal carcinomas in situ, and
to be increasingly expressed in invasive breast cancer (88%)
and its metastases (100%). These data were confirmed by
immunohistochemistry and western blot analysis by using a
collection of 16 monoclonal antibodies for the detection of
various chains of laminin. Interestingly, a similar switch from β2-
containing to β1-containing vascular laminins has also been
shown to occur during the progression of brain gliomas [18]
and may constitute a general feature of vascular BM changes
in solid tumors.
The importance of the present paper by Fujita and colleagues
[4] is that it is the first demonstration of specific laminin
isoform changes in pre-invasive (ductal carcinoma in situ)
and invasive breast ductal carcinoma together with its
metastases in comparison with normal breast tissues. The β1
chain of laminin-2, laminin-8, and laminin-10 is detected in
newly formed tumor vessels and might be a potential target
for antiangiogenic therapy.
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